ArticleOncotarget2021
Total lesion glycolysis in oral squamous cell carcinoma as a biomarker derived from pre-operative FDG PET/CT outperforms established prognostic factors in a newly developed multivariate prediction model.
Article in Oncotarget, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Nodal status dictates divergent prognostic drivers in oral squamous cell carcinoma: metabolic burden in pN0 vs. sarcopenia and nodal burden in pN.Frontiers in oncology · 2026Article
- Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Review
- Article
- Salivary Metabolomics for Prognosis of Oral Squamous Cell Carcinoma.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRetrospective study to investigate the impact of image derived biomarkers from [ MATERIALS AND
methods127 subsequent patients with biopsy-proven OSCC were included who underwent [
resultsDuring follow-up 52 (41%) of the patients died. Median OS was longer for patients with lower MTV or lower TLG. SUV
conclusionsThe pre-therapeutic [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.